Bluejay Diagnostics Sees Positive Trial Results for Interleukin-6

Dow Jones06-26

By Chris Wack

Bluejay Diagnostics said it saw positive results from the primary analysis of a clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and septic shock.

The company said the primary analysis of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the intensive care unit may predict patient mortality out to 28 days.

A secondary outcome of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary outcomes showed that lactate and sequential organ failure assessment, standard clinical tests used for sepsis and septic shock patients, weren't predictors of patient mortality out to 28 days.

Bluejay Diagnostics is planning to begin its next clinical study in the third quarter of 2024. If the results are positive, the company intends to use the study as support in a 510(k) application to the Food and Drug Administration in 2025.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 26, 2024 08:19 ET (12:19 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446395367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-26 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446395367","market":"nz","top_or_hot":-1,"title":"Bluejay Diagnostics Sees Positive Trial Results for Interleukin-6","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n   Bluejay Diagnostics said it saw positive results from the primary analysis of a clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and septic shock. \n</p>\n<p>\n  The company said the primary analysis of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the intensive care unit may predict patient mortality out to 28 days. \n</p>\n<p>\n  A secondary outcome of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary outcomes showed that lactate and sequential organ failure assessment, standard clinical tests used for sepsis and septic shock patients, weren't predictors of patient mortality out to 28 days. \n</p>\n<p>\n  Bluejay Diagnostics is planning to begin its next clinical study in the third quarter of 2024. If the results are positive, the company intends to use the study as support in a 510(k) application to the Food and Drug Administration in 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2024 08:19 ET (12:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluejay Diagnostics Sees Positive Trial Results for Interleukin-6</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluejay Diagnostics Sees Positive Trial Results for Interleukin-6\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-26 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n   Bluejay Diagnostics said it saw positive results from the primary analysis of a clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BJDX","symbol_name":"Bluejay Diagnostics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2446395367","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446395367","pubTimestamp":1719404340,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bluejay Diagnostics said it saw positive results from the primary analysis of a clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and septic shock.The company said the primary analysis of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the intensive care unit may predict patient mortality out to 28 days.A secondary outcome of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary outcomes showed that lactate and sequential organ failure assessment, standard clinical tests used for sepsis and septic shock patients, weren't predictors of patient mortality out to 28 days.Bluejay Diagnostics is planning to begin its next clinical study in the third quarter of 2024. If the results are positive, the company intends to use the study as support in a 510 application ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BJDX":"Bluejay Diagnostics Inc","BK4082":"医疗保健设备"},"translate_title":"Bluejay Diagnostics看到白细胞介素-6的积极试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BJDX":1},"content_text":"By Chris Wack \n\n\n \n\n\n   Bluejay Diagnostics said it saw positive results from the primary analysis of a clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and septic shock. \n\n\n  The company said the primary analysis of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the intensive care unit may predict patient mortality out to 28 days. \n\n\n  A secondary outcome of the study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary outcomes showed that lactate and sequential organ failure assessment, standard clinical tests used for sepsis and septic shock patients, weren't predictors of patient mortality out to 28 days. \n\n\n  Bluejay Diagnostics is planning to begin its next clinical study in the third quarter of 2024. If the results are positive, the company intends to use the study as support in a 510(k) application to the Food and Drug Administration in 2025. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2024 08:19 ET (12:19 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446395367"}